Vonicog alfa for severe von Willebrand disease

NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
People with von Willebrand disease either have a deficiency of a blood protein called von Willebrand factor, or this protein doesn't work properly. This means that their blood cannot clot properly and they are prone to prolonged or excessive bleeding. There are three different types of von Willebrand disease – types 1, 2, and 3. Type 3 is rare and people with this type have very low levels of von Willebrand factor in their blood, or none at all. Vonicog alfa is a new drug that is given in a drip (directly into a vein). It is being studied to see whether it reduces bleeding in people with severe von Willebrand disease, and that it is safe to use. If vonicog alfa is licensed for use in the UK, it could provide a new treatment for people with severe von Willebrand disease.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/vonicog-alfa-for-severe-von-willebrand-disease/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; von Willebrand Diseases; von Willebrand Factor; Blood Proteins; Hemorrhage; Thrombosis

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000752

Date abstract record published
14/06/2016